Full-Time

Post Market Surveillance Engineer 2

Posted on 6/13/2026

Integer Holdings Corporation

Integer Holdings Corporation

1,001-5,000 employees

Medical device CDMO for cardiac devices

Compensation Overview

$71k - $104.1k/yr

+ Cash-based incentive program

Plymouth, MN, USA

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
FDA Regulations
Visio
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Integer Holdings Corporation

See people who can refer or advise you

Requirements
  • A bachelor's degree and at least 1 year of relevant experience; candidates without the degree may be considered with at least 3 years of relevant experience.
  • Ability to work independently and collaboratively with associates and cross-functional teams.
  • Solid technical aptitude and ability to contribute technically as an individual or team member.
  • Competence in written and oral communication.
  • Ability to organize and track multiple projects and complaints simultaneously.
  • Intermediate to advanced proficiency with Microsoft Office, including PowerPoint, Visio, Project, Excel, and Word.
  • Ability to handle, decontaminate, and analyze products used in the field, with relevant vaccinations when required.
Responsibilities
  • Execute and support complaint handling, regulatory reporting, and post-market surveillance processes under the guidance of experienced associates and managers.
  • Analyze, evaluate, and investigate customer complaints in compliance with FDA 21 CFR Quality System Regulation requirements and other applicable regulatory requirements.
  • Capture and document complaints in the complaint handling database according to internal policies and procedures.
  • Send complaint acknowledgements to customers and track returned customer products.
  • Perform complaint investigations with cross-functional team members.
  • Review device history records for nonconformities related to alleged complaints.
  • Gather information from internal and external customers and prepare customer communications, complaint investigation reports, and customer-facing reports.
  • Collect data, conduct root-cause investigations, and support resolution of product-quality and patient-safety complaints.
  • Ensure timely closure of complaint investigations in compliance with applicable regulations.
  • Perform risk assessments for Integer-owned product designs.
  • Perform Corrective and Preventive Action assessments and support investigations.
  • Assess adverse-event reportability decisions under United States and international regulations.
  • Assist with forms for submitting reportable complaints to applicable agencies.
  • Gather complaint and shipping data to support post-market trending, Post-Market Surveillance Reports, and Periodic Safety Update Reports.
  • Support internal and external audits, regulatory inspections, and customer audits, including responding to and closing audit observations and findings.
  • Work on quality-system projects using standard methodologies to investigate process-improvement opportunities.
  • Assure adherence to the Quality Management System, facilitate or contribute to corrective and preventive actions, and support quality key performance indicators.
  • Support Manufacturing Excellence and Market Focused Innovation strategies.
  • Participate in or lead site Hoshin planning, quality planning, validation master plans, and quality-improvement initiatives.
  • Provide leadership for quality-assurance and regulatory-affairs metrics as required.
  • Lead sustained-change activities, including initiating and completing customer change notifications, and support continuous improvement.
  • Support workplace organization and visual controls, Manufacturing Standard Work, and training and certification programs.
  • Promote associate engagement through standardized problem-solving, behavior-based safety programs, and improvement-idea systems.
  • Support systems and process optimization through built-in-quality principles.
  • Support Environmental, Health and Safety programs, site quality key performance indicators, continuous-improvement suggestions, and their implementation.
Desired Qualifications
  • Medical device or other regulated-industry experience.
Integer Holdings Corporation

Integer Holdings Corporation

View

Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

1940

Get referred to Integer Holdings Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • KKR will pay $127 cash per share, a 51.8% premium.
  • Q2 2026 adjusted EPS hit $1.60, beating estimates by 15.9%.
  • KKR plans capacity, technology, innovation, and employee ownership investments after closing.

What critics are saying

  • New Ross shut for two unpaid weeks July 27-August 10, signaling demand volatility.
  • Q2 2026 sales fell 2.6% to $464.1 million, with organic sales down 1.5%.
  • Post-deal, Integer delists from NYSE and disappears if approvals or financing break.

What makes Integer Holdings Corporation unique

  • KKR’s August 3, 2026 bid validates Integer’s critical medtech CDMO platform.
  • Integer supplies components for cardiovascular, neuromodulation, and orthopedic devices across major manufacturers.
  • The New Ross facility remains strategically important, with recent capacity and technology investments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Adoption Assistance

Parental Leave

401(k) Company Match

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Company News

Ticker Report
Aug 29th, 2026
Boussard & Gavaudan Gestion Sas Makes New $2.60 Million Investment in Integer Holdings Corporation $ITGR

Boussard & Gavaudan Gestion Sas bought a new position in Integer Holdings Corporation (NYSE:ITGR – Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 28,153 shares of the medical equipment provider’s stock, valued at approximately $2,597,000. Other institutional investors and hedge funds also […]

Yahoo Finance
Aug 16th, 2026
Healthcare stocks outpace S&P 500 by 13 percentage points over six months

Healthcare stocks have returned 26.1% over the past six months, outperforming the S&P 500 by 13.1 percentage points. However, investors must remain cautious due to heavy regulation affecting earnings potential. Integer Holdings faces concerns with 6.1% annual revenue growth over two years, lagging healthcare peers. Its modest revenue base of $1.84 billion provides less fixed cost leverage than larger competitors. The company trades at $125.07 per share, or 18.6 times forward price-to-earnings. Evolent Health shows weak platform performance and declining returns on capital. Its high net-debt-to-EBITDA ratio of 7 times could force unfavourable capital raises if market conditions worsen. Shares trade at $4.15, representing 12.4 times forward price-to-earnings. Tenet Healthcare, operating hospitals and surgical centres across nine US states, emerges as the recommended healthcare investment.

Yahoo Finance
Aug 4th, 2026
Integer Holdings acquired by KKR for $5.7B in all-cash deal at $127 per share

Integer Holdings agreed to be acquired by private equity firm KKR in an all-cash deal valued at approximately $5.7 billion. The transaction values the medical technology company at $127 per share. Shares jumped 2.7% in afternoon trading, continuing a rally from the previous session when the stock surged over 20% following the announcement. The acquisition news overshadowed strong second-quarter results, where Integer posted an adjusted profit of $1.60 per share on $464.1 million in revenue, surpassing analyst estimates. Following the buyout announcement, Integer withdrew its previously issued financial guidance and cancelled its upcoming earnings conference call. Shares traded at $124.50, marking a new 52-week high.

BizWire Express
Aug 3rd, 2026
KKR to acquire Integer for $5.7B in all-cash deal at $127 per share

KKR has agreed to acquire Integer Holdings Corporation, a medical device contract development and manufacturing organisation, in an all-cash transaction valued at approximately $5.7 billion. Integer stockholders will receive $127 per share, representing a 51.8% premium to the company's closing share price on 29 April 2026. The acquisition follows a comprehensive strategic review announced by Integer in April 2026. The Integer Board unanimously approved the agreement and recommends stockholder approval. KKR plans to invest in Integer's capacity, technology, innovation, and talent. The firm also intends to establish a broad-based employee ownership programme following the transaction's close, consistent with its approach across portfolio companies. The transaction is expected to close by year-end, subject to stockholder approval and regulatory clearances. Upon completion, Integer will become privately held and delist from the New York Stock Exchange.

Yahoo Finance
Aug 3rd, 2026
Integer Holdings beats Q2 expectations with $464M revenue and $1.60 earnings per share

Integer Holdings Corp. reported second-quarter net income of $23.6 million, or 69 cents per share. Adjusted earnings came to $1.60 per share, exceeding Wall Street expectations of $1.38 per share. The Plano, Texas-based medical device outsource manufacturer posted revenue of $464.1 million for the period, also beating analyst forecasts of $452.5 million. The results surpassed predictions from five analysts surveyed by Zacks Investment Research on both earnings and revenue metrics.

INACTIVE